{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:11:45Z","timestamp":1790914305617,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The introduction of emicizumab, a bispecific antibody that mimics factor VIII (FVIII) function, has raised critical questions regarding the potential for FVIII inhibitor development when patients receiving emicizumab prophylaxis are administered FVIII during high-risk clinical scenarios. To investigate this concern, we developed a novel human hemophilia A (HemoAhfIX\/hfX) mouse model by adeno-associated virus delivery of human F9 and F10 genes as episomal copies, which expressed sufficient levels of human FIX and FX (158.0 \u00b1 57.9 international units [IU]\/dL and 372.8 \u00b1 170.7 IU\/dL, respectively, at 12 weeks). Emicizumab treatment in HemoAhfIX\/hfX mice significantly shortened activated partial thromboplastin time and partially restored thrombin generation capacity. Using a 2-factor factorial design, 55 mice were assigned to 4 treatment groups: (A) FVIII prophylaxis, (B) on-demand FVIII, (C) emicizumab with FVIII prophylaxis, and (D) emicizumab with on-demand FVIII. On-demand groups received weekly knee joint puncture injuries to simulate bleeding episodes throughout the experimental period. Although most animals developed high-titer inhibitors, limiting the detection of intergroup differences in inhibitor development rates, inhibitor titers varied significantly across treatment groups (P = .0098), with notably lower levels in emicizumab-treated mice (P = .0006). In addition, emicizumab treatment preserved joint architecture, evidenced by reduced synovitis. These findings demonstrate that emicizumab therapy is associated with attenuated inhibitor titers and enhanced joint preservation against bleeding in HemoAhfIX\/hfX mice, establishing this model as a valuable platform for preclinical evaluation of emicizumab-based therapeutic strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018691","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T18:58:03Z","timestamp":1772737083000},"page":"3118-3127","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Development of a novel hemophilia A mouse model to study emicizumab and factor VIII inhibitor risk"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4121-019X","authenticated-orcid":false,"given":"Sheng-Chieh","family":"Chou","sequence":"first","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Ting","family":"Chang","sequence":"additional","affiliation":[{"name":"2Department of Clinical Laboratory Science and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Fu","family":"Chen","sequence":"additional","affiliation":[{"name":"2Department of Clinical Laboratory Science and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hong","family":"Tsai","sequence":"additional","affiliation":[{"name":"1Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Yu","family":"Cheng","sequence":"additional","affiliation":[{"name":"3Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Pu","family":"Sun","sequence":"additional","affiliation":[{"name":"4Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Hua","family":"Tao","sequence":"additional","affiliation":[{"name":"4Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0888-9153","authenticated-orcid":false,"given":"Chia-Lun","family":"Hong","sequence":"additional","affiliation":[{"name":"2Department of Clinical Laboratory Science and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua-Lin","family":"Wu","sequence":"additional","affiliation":[{"name":"5Department of Biochemistry and Molecular Biology, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6748-5581","authenticated-orcid":false,"given":"Shu-Wha","family":"Lin","sequence":"additional","affiliation":[{"name":"2Department of Clinical Laboratory Science and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan"},{"name":"3Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"2026050815180366400_bib1","author":"Mehta","year":"2022"},{"issue":"7","key":"2026050815180366400_bib2","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1542\/pir.34.7.289","article-title":"Hemophilia: in review","volume":"34","author":"Zimmerman","year":"2013","journal-title":"Pediatr Rev"},{"issue":"suppl 6","key":"2026050815180366400_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"issue":"1","key":"2026050815180366400_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1365-2516.2006.01189.x","article-title":"Practice patterns in haemophilia A therapy - global progress towards optimal care","volume":"12","author":"Geraghty","year":"2006","journal-title":"Haemophilia"},{"issue":"10040","key":"2026050815180366400_bib5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"2026050815180366400_bib6","first-page":"30","article-title":"The target joint in severe hemophilia A","volume":"17","author":"Kendre","year":"2020","journal-title":"Pediatr Oncall J"},{"issue":"3","key":"2026050815180366400_bib7","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jfma.2021.07.017","article-title":"Evolution of congenital haemophilia care in Taiwan","volume":"121","author":"Chen","year":"2022","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"2026050815180366400_bib8","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2026050815180366400_bib9","doi-asserted-by":"crossref","first-page":"102696","DOI":"10.1016\/j.rpth.2025.102696","article-title":"Contemporary approaches to treat people with hemophilia: what's new and what's not?","volume":"9","author":"Valentino","year":"2025","journal-title":"Res Pract Thromb Haemost"},{"issue":"21","key":"2026050815180366400_bib10","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"2026050815180366400_bib11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1182\/blood.2019000658","article-title":"Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A","volume":"134","author":"van den Berg","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2026050815180366400_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2040620712464509","article-title":"Factor VIII inhibitors in hemophilia A: rationale and latest evidence","volume":"4","author":"Witmer","year":"2013","journal-title":"Ther Adv Hematol"},{"issue":"1 suppl 1","key":"2026050815180366400_bib13","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1053\/j.seminhematol.2003.11.016","article-title":"Environmental and genetic factors influencing inhibitor development","volume":"41","author":"Oldenburg","year":"2004","journal-title":"Semin Hematol"},{"issue":"suppl 77","key":"2026050815180366400_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ejh.12495","article-title":"Genetic risk factors for inhibitors in haemophilia A","volume":"94","author":"Bardi","year":"2015","journal-title":"Eur J Haematol"},{"issue":"4","key":"2026050815180366400_bib15","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.jtha.2024.12.039","article-title":"Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature","volume":"23","author":"van Stam","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"11","key":"2026050815180366400_bib16","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"issue":"20","key":"2026050815180366400_bib17","doi-asserted-by":"crossref","first-page":"4046","DOI":"10.1182\/blood-2012-09-457036","article-title":"Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study","volume":"121","author":"Gouw","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2026050815180366400_bib18","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2026050815180366400_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.18379","article-title":"Current and future therapies for haemophilia-beyond factor replacement therapies","volume":"200","author":"Nogami","year":"2022","journal-title":"Br J Haematol"},{"issue":"23","key":"2026050815180366400_bib20","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2017-08-801662","article-title":"Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?","volume":"130","author":"Lenting","year":"2017","journal-title":"Blood"},{"issue":"10","key":"2026050815180366400_bib21","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/nm.2942","article-title":"A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model","volume":"18","author":"Kitazawa","year":"2012","journal-title":"Nat Med"},{"issue":"9","key":"2026050815180366400_bib22","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"issue":"9","key":"2026050815180366400_bib23","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"issue":"24","key":"2026050815180366400_bib24","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"134","author":"Young","year":"2019","journal-title":"Blood"},{"issue":"14","key":"2026050815180366400_bib25","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood.2023021832","article-title":"Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial","volume":"143","author":"Pipe","year":"2024","journal-title":"Blood"},{"issue":"20","key":"2026050815180366400_bib26","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2014-07-585737","article-title":"Anti-factor IXa\/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A","volume":"124","author":"Muto","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2026050815180366400_bib27","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1182\/blood.2019004334","article-title":"A hemophilia A mouse model for the in vivo assessment of emicizumab function","volume":"136","author":"Ferriere","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2026050815180366400_bib28","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/ejh.13610","article-title":"Recombinant factor VIII Fc for the treatment of haemophilia A","volume":"106","author":"Hermans","year":"2021","journal-title":"Eur J Haematol"},{"issue":"8","key":"2026050815180366400_bib31","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/j.1538-7836.2010.03913.x","article-title":"Generation of a novel factor IX with augmented clotting activities in vitro and in vivo","volume":"8","author":"Lin","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"6","key":"2026050815180366400_bib29","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2516.2006.01348.x","article-title":"Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis","volume":"12","author":"Valentino","year":"2006","journal-title":"Haemophilia"},{"issue":"2","key":"2026050815180366400_bib30","doi-asserted-by":"crossref","first-page":"e214","DOI":"10.1111\/hae.14264","article-title":"Approximation of emicizumab plasma levels in emergency situations. A practical approach","volume":"27","author":"Pekrul","year":"2021","journal-title":"Haemophilia"},{"key":"2026050815180366400_bib32","unstructured":"University E, Genentech I\n          . Emicizumab PUPs and Nuwiq ITI Study. Accessed 12 March 2026. https:\/\/classic.clinicaltrials.gov\/show\/NCT04030052."},{"issue":"5","key":"2026050815180366400_bib33","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1538-7933.2004.00671.x","article-title":"Induction of immune tolerance by neonatal intravenous injection of human factor VIII in murine hemophilia A","volume":"2","author":"Madoiwa","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"9","key":"2026050815180366400_bib34","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1111\/j.1538-7836.2010.03962.x","article-title":"Blood-induced joint disease: the pathophysiology of hemophilic arthropathy","volume":"8","author":"Valentino","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026050815180366400_bib35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/j.1365-2516.2008.01689.x","article-title":"Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes","volume":"14","author":"Hakobyan","year":"2008","journal-title":"Haemophilia"},{"issue":"2","key":"2026050815180366400_bib36","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/hae.14951","article-title":"Bone mineral density in haemophilia patients: a systematic review and meta-analysis","volume":"30","author":"Zhang","year":"2024","journal-title":"Haemophilia"},{"issue":"2","key":"2026050815180366400_bib37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/hae.70215","article-title":"Bone health in adults with severe haemophilia receiving different prophylactic treatments","volume":"32","author":"Lyu","year":"2026","journal-title":"Haemophilia"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3118\/2516207\/blooda_adv-2025-018691-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3118\/2516207\/blooda_adv-2025-018691-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:18:11Z","timestamp":1778267891000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3118\/566935\/Development-of-a-novel-hemophilia-A-mouse-model-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018691","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,1]]}}}